GQ-303 / GQ Bio Therap - LARVOL DELTA

Pacira BioSciences Announces Equity Investment in GeneQuine Biotherapeutics (GlobeNewswire) - "Pacira BioSciences...today announced that the company will lead an equity investment in GeneQuine Biotherapeutics GmbH. Under the terms of the agreement, Pacira will make an initial investment of €2.0 million with an additional €4.0 million investment predicated upon GeneQuine achieving certain prespecified near-term milestones related to its lead gene therapy product candidate, GQ-303...Safety of this platform has been demonstrated in several species and is currently being evaluated in an ongoing Phase 1 study. GQ-303 and its analogs are currently in preclinical development as a treatment for OA."

Licensing / partnership • Osteoarthritis • Pain